NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Renal Impairment Study of PF-06700841

CompletedPhase 1

Sponsor: Pfizer

Conditions: Healthy Volunteer, Renal Impairment

Interventions: PF-06700841

Countries: United States

The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney disease.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female participants who are between the ages of 18 and 75 years, inclusive, at the Screening visit.
* Body mass index (BMI) of ≥17.5 to ≤40 kg/m2; and a total body weight \>50 kg.
* Normal, Severe, Moderate and Mild renal function at 2 Screening visits.
* Stable drug regimen

Exclusion Criteria:

* Renal transplant recipients.
* Urinary incontinence without catheterization.
* Subjects with clinically significant infections within the past 6 months prior to first dose of study drug, evidence of active or chronic infection requiring oral treatment within 4 weeks prior to first dose
* Known history of pulmonary embolism or recurrent deep vein thrombosis
* Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).

Locations (3)

Miami, Florida, United States
Miami, Florida, United States
Saint Paul, Minnesota, United States